(12/20) complete response rate after treatment with EO2463 in combination with lenalidomide and rituximab (R2) <li /> EO ...

Drug resistance in solid tumors remains a major obstacle in oncology, frequently leading to treatment failure and disease relapse. A central contributor to ...

Cancer plasticity allows tumor cells to change their identity, evade therapies, and adapt to environmental pressures, contributing to treatment resistance and metastasis. New research is targeting ...

Immunotherapy, which uses the body's own immune system to fight cancer, is an effective treatment option, yet many patients do not respond to it. Thus, cancer researchers are seeking new ways to ...

Lung cancer leads global cancer mortality, and non-small-cell variants make up more than 80% of cases. Immune checkpoint inhibitors have transformed therapy yet help only 27–45% of recipients. ...

Colorectal cancer happens when cells in the colon or rectum (parts of the large intestine) begin to grow out of control. This happens because of changes, or mutations, in the DNA inside the cells. But ...

Hyperthermia, a cancer treatment using controlled heat to kill tumor cells, shows promise but faces limitations due to some ...

Pheast Therapeutics, a clinical-stage biotechnology company developing novel therapies to unleash the power of macrophages on aggressive, difficult-to-treat cancers, today announced that the U.S. Food ...